Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida

Current Medical Research and Opinion
Damon TantonRobert A Bailey

Abstract

Clinical trials and real-world studies reported that canagliflozin (CANA) improved HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM). This study examines if previous results hold regionally and within specific patient sub-groups. Adults with T2DM and ≥12 months of clinical activity before the first CANA prescription (index) were identified in electronic medical records (January 1, 2012-February 15, 2017) from a network of hospitals in Florida. Quality measures were described at baseline and 3, 6, 9, and 12 months post-index. Selected thresholds were HbA1c < 7%, BP < 140/90 mmHg, and weight loss ≥5%. Sub-groups included patients ≥65 years old, with African American race, with CANA dose increase, initiating CANA in an endocrinology setting, and initiating CANA in a primary care setting. Overall, 1,259 patients (mean age = 56.7 years; 51.2% female, 70.4% White) were identified. Among patients with a baseline HbA1c ≥ 7%, 16.1% had an HbA1c < 7% 3 months following CANA initiation, and the mean HbA1c decreased from 8.8% to 8.1%. Among patients with a baseline systolic BP ≥140 mmHg or diastolic BP ≥ 90 mmHg, 59.3% attained a systolic BP < 140 mmHg and 77.3% a diastolic BP < 90 mmHg after 3 months....Continue Reading

References

Jan 22, 2005·Science·Christopher J Rhodes
Jun 28, 2007·International Journal of Clinical Practice. Supplement·E Standl
Mar 17, 2010·The American Journal of Medicine·Mark Stolar
Nov 15, 2011·Diabetes Research and Clinical Practice·David R WhitingJonathan Shaw
Mar 8, 2013·Diabetes, Obesity & Metabolism·J-F YaleG Meininger
Nov 23, 2013·Parkinsonism & Related Disorders·Roselyne M RijsmanMaartje Louter
Apr 12, 2014·Current Opinion in Virology·Ragunath SingaraveluJohn Paul Pezacki
Dec 30, 2014·Diabetes Care
Mar 18, 2015·Lancet·Thaminda LiyanageVlado Perkovic
Jun 30, 2015·Current Medical Research and Opinion·James R GavinGary Meininger
Apr 1, 2014·Clinical Diabetes : a Publication of the American Diabetes Association·Dawn M Battise
Oct 10, 2015·Diabetes, Obesity & Metabolism·Greg FulcherUNKNOWN CANVAS trial collaborative group
Mar 10, 2016·Obstetrics and Gynecology·Silvio E Inzucchi, Sachin K Majumdar
Aug 20, 2016·Journal of the American Society of Nephrology : JASN·Hiddo J L HeerspinkVlado Perkovic
Sep 21, 2016·Current Medical Research and Opinion·June Felice JohnsonRobert Bailey
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group

❮ Previous
Next ❯

Citations

Feb 5, 2021·Future Cardiology·Vivencio Barrios, Carlos Escobar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.